Q-omics provides the consensus-scored MIR181A2HG profile across patient tissues and cancer cell-line models. MIR181A2HG expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR181A2HG is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MIR181A2HG RNA expression shows 19,262 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, THCA, and ACC as cancer lineages where MIR181A2HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR181A2HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR181A2HG survival associations across molecular data types. MIR181A2HG RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR181A2HG RNA expression–survival associations across cancer types. High MIR181A2HG expression shows unfavorable associations in ACC, KIRC and COAD, but favorable associations in UCS, THCA and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for MIR181A2HG RNA expression.
This table summarizes MIR181A2HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR181A2HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR181A2HG shows lower tumor expression in KICH and higher tumor expression in THCA, LIHC, HNSC, COAD and BLCA. The THCA box plot shows higher MIR181A2HG RNA expression in tumor versus normal tissue (log2 FC = +1.808, t-test p < 0.001).
This table shows molecular features associated with MIR181A2HG in patient tissues and cancer cell lines. In patient samples, MIR181A2HG shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
